icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
Safety and Pharmacodynamics of Oral TLR-7 Agonist
GS-9620 in Patients With Chronic Hepatitis B

 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
 
Edward J. Gane,1 Eric Sicard,2 Stuart C. Gordon,3 Daniel Gruener,4 Stuart K. Roberts,5 Suzanne Kim,6 Wendy Cheng,7 Carla S. Coffin,8 Richard Fedorak,9 Paul Y. Kwo,10 Barbara A. Leggett,11 Daryl Lau,12 Young-Suk Lim,13 Y.J. Kim,14 Stefan Pflanz,15 Benedetta Massetto,15 Mani Subramanian,15 John G. McHutchison,15 Bradley Freilich,16 Kumar Visvanathan17
1Auckland Clinical Studies, Auckland, New Zealand; 2Algorithme Pharma, Inc., Montreal, Quebec, Canada; 3Henry Ford Health Systems, Detroit, MI; 4CRI Worldwide, LLC, Philadelphia, PA; 5Alfred Hospital, Melbourne, Australia; 6West Coast Clinical Trials, LLC, Costa Mesa, CA;
7Royal Perth Hospital, Perth, Australia; 8University of Calgary, Alberta, Canada; 9University of Alberta Hospital, Edmonton, Canada; 10Indiana University, Indianapolis, IN; 11Royal Brisbane and Women's Hospital, Brisbane, Australia; 12Beth Israel Deaconess Medical Center, Boston, MA;
13Asan Medical Center, Seoul, South Korea; 14Seoul National University Hospital, Seoul; 15Gilead Sciences, Inc, Foster City, CA; 16Kansas City Research Institute, Kansas City, MO; 17Southern Health, Monash University and St. Vincent's Hospital, University of Melbourne, Australia

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif